You just read:

Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban

News provided by

Daiichi Sankyo Company, Limited; Perosphere Inc.

Apr 25, 2013, 07:00 ET